2013

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

Timothy J. Ley
Washington University School of Medicine in St. Louis

Christopher Miller
Washington University School of Medicine in St. Louis

Li Ding
Washington University School of Medicine in St. Louis

Jack Baty
Washington University School of Medicine in St. Louis

Lucinda Fulton
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
http://digitalcommons.wustl.edu/open_access_pubs/2479

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network

ABSTRACT

BACKGROUND
Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.

METHODS
We analyzed the genomes of 200 clinically annotated adult cases of de novo AML, using either whole-genome sequencing (50 cases) or whole-exome sequencing (150 cases), along with RNA and microRNA sequencing and DNA-methylation analysis.

RESULTS
AML genomes have fewer mutations than most other adult cancers, with an average of only 13 mutations found in genes. Of these, an average of 5 are in genes that are recurrently mutated in AML. A total of 23 genes were significantly mutated, and another 237 were mutated in two or more samples. Nearly all samples had at least 1 nonsynonymous mutation in one of nine categories of genes that are almost certainly relevant for pathogenesis, including transcription-factor fusions (18% of cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%), DNA-methylation–related genes (44%), signaling genes (59%), chromatin-modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and spliceosome-complex genes (14%). Patterns of cooperation and mutual exclusivity suggested strong biologic relationships among several of the genes and categories.

CONCLUSIONS
We identified at least one potential driver mutation in nearly all AML samples and found that a complex interplay of genetic events contributes to AML pathogenesis in individual patients. The databases from this study are widely available to serve as a foundation for further investigations of AML pathogenesis, classification, and risk stratification. (Funded by the National Institutes of Health.)
The molecular pathogenesis of acute myeloid leukemia (AML) has been studied with the use of cytogenetic analysis for more than three decades. Recurrent chromosomal structural variations are well established as diagnostic and prognostic markers, suggesting that acquired genetic abnormalities (i.e., somatic mutations) have an essential role in pathogenesis. However, nearly 50% of AML samples have a normal karyotype, and many of these genomes lack structural abnormalities, even when assessed with high-density comparative genomic hybridization or single-nucleotide polymorphism (SNP) arrays (see Glossary). Targeted sequencing has identified recurrent mutations in FLT3, NPM1, KIT, CEBPA, and TET2. Massively parallel sequencing enabled the discovery of recurrent mutations in DNMT3A and IDH1. Recent studies have shown that many patients with AML carry no mutations in any of the currently recognized driver genes associated with the pathogenesis of AML.

Patients with a cytogenetic profile that is associated with a favorable risk (i.e., those with PML-RARA, RUNX1-RUNX1T1, or MYH11-CBFB fusions) have relatively good outcomes with chemotherapy-based consolidation regimens, whereas patients with an unfavorable-risk profile (monosomy karyotype or complex alterations) require allogeneic transplantation during the first remission to improve their prognosis. However, the majority of patients with AML have an intermediate cytogenetic risk (most commonly, a normal karyotype); some of these patients do well with chemotherapy consolidation, but others have a very poor outcome. For this reason, recent studies have focused on establishing new biomarkers for better classification of intermediate risk. Newer classification algorithms incorporate FLT3, NPM1, CEBPA, and KIT into standard-of-care testing. Even more recently, testing has revealed that mutations in newly discovered AML genes (e.g., DNMT3A, IDH1/2, and TET2) may also provide prognostic information for some patients with an intermediate-risk profile. None of the current classification schemes are entirely accurate, which suggests that a more complete understanding of the genetic and epigenetic changes that are relevant to the pathogenesis of AML will be required for better classification of risk and, ultimately, better approaches to therapy.

**METHODS**

**PATIENTS**

We selected samples from 200 adults with de novo AML to represent the major morphologic and cytogenetic subtypes of AML. The characteristics of these patients are fully described in Table 1, and in Tables S1 and S2, Figure S1, and

---

**Glossary**

**Comparative genomic hybridization:** An array-based method that permits comparison of DNA abundance throughout the genome between two DNA samples to identify regions where DNA copies have been gained or lost.

**DNA methylation:** This generally refers to the addition of a methyl group to the 5-carbon of the pyrimidine ring of cytosine, usually pertaining to cytosines that precede a guanine residue in DNA (a CpG dinucleotide motif). DNA methylation of CpG-rich regions (CpG islands) is often associated with repression of nearby genes.

**MicroRNA:** A short regulatory form of RNA that binds to a target RNA and suppresses its translation or alters its stability.

**Single-nucleotide polymorphism (SNP) array:** A microarray-based assay system that allows for simultaneous measurement of nucleotide sequence of hundreds of thousands of SNPs throughout the genome in a DNA sample. Acquired copy-number variants can sometimes be detected with SNP arrays by comparing signals from the tumor and normal samples obtained from the same individual.

**Single-nucleotide variant (SNV):** A difference in a DNA sequence at a single position in the genome, as compared with the reference genome; each variant may represent either an inherited or an acquired (somatic) change. SNPs generally reflect inherited changes only.

**Variant-allele clusters:** Groups of mutations with similar variant allele frequencies, defined by statistical approaches.

**Variant-allele frequency (VAF):** The relative proportion of sequencing reads from a variant allele (i.e., somatic mutation) in a tumor sample. The VAF can be used to estimate the fraction of cells within a sample that contain that variant. For example, variant alleles with a VAF of 50% usually represent heterozygous somatic mutations that are present in all cells within the sample. Variant alleles with lower VAFs are generally present in only a fraction of the cells in a sample, which may represent subclones derived from the founding clone of a tumor.

**Whole-exome sequencing:** Sequencing of the coding regions, or exons, of an entire genome from a single individual.

**Whole-genome sequencing:** Determination of the primary nucleotide sequence of the entire genome from a single individual.
the Materials section in the Supplementary Appendix, available with the full text of this article at NEJM.org. A video describing AML and this study is also available at NEJM.org.

**Analytic Platforms**

We performed whole-genome sequencing of the primary tumor and matched normal skin samples from 50 patients (with data from 24 of these patients reported previously) and exome capture and sequencing for another 150 paired samples of AML tumor and skin (see Table S3 in the Supplementary Appendix for coverage data for the 200 samples).

All 200 patients who were selected for this study were enrolled in a single-institution tissue-banking protocol approved by the human studies committee at Washington University. Written informed consent for whole-genome sequencing was obtained from all study participants.

The samples, which were banked between November 2001 and March 2010, were selected from a set of more than 400 samples to reflect a real-world distribution of subtypes. Sample inventory and quality issues also had to be considered in the selection process, since the samples were analyzed on several different platforms. We identified candidate somatic variants using several algorithms (see the Methods section in the Supplementary Appendix), and all the variants for the 200 samples were verified with the use of hybridization capture–based methods and deep digital sequencing. We performed RNA-expression profiling on the Affymetrix U133 Plus 2 platform for 197 samples, RNA sequencing for 179 samples, microRNA (miRNA) sequencing for 194 samples, Illumina Infinium HumanMethylation450 BeadChip profiling for 192 samples, and Affymetrix SNP Array 6.0 for both tumor and normal skin samples from all 200 patients. Data sets were not completed for all samples on all platforms because of assay failures and availability and quality issues for some samples. The complete list of data sets is provided in Table S4 in the Supplementary Appendix. All data sets are available through the Cancer Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.gov/tcga).

**Results**

**Copy-Number Alterations**

In most de novo AML samples with a cytogenetic profile indicating intermediate or favorable risk, we detected very few copy-number events on high-resolution SNP arrays, as reported previously (Fig. S2 and Table S5 in the Supplementary Appendix). Unfavorable-risk samples had chromosomal copy-number alterations that were verified on the SNP arrays, and many had additional, cytogenetically cryptic events. No samples contained evidence of chromothripsis (a single genomic event that results in focal losses and rearrangements in multiple genomic regions). Details of these analyses are presented in the Materials section in the Supplementary Appendix.

**Mutations in Coding Sequences**

We discovered 2315 somatic single-nucleotide variants (SNVs) and 270 small insertions and deletions (indels) in coding (tier 1) regions of the genome, with an average of 13 tier 1 mutations per sample (range, 0 to 51) (see box, and Table S6 in the Supplementary Appendix). We observed no recurring coding mutations in three samples, but all contained well-recognized fusion events that are known to initiate AML (NUP98-NSD1 in Patient 868231, MLL-MLLT3/AF9 in Patient 923966, and MLL-MLLT10/AF10 in Patient 558395). Outlier samples contained 51, 36, and 35 tier 1 mutations; none of these samples contained mutations in known DNA-repair genes. Of the 2315 SNVs, 1539 (66%) were missense and 510 (22%) had no translational consequences. Small indels accounted for 270 of the 2585 validated mutations (10%); of these, 191 (71%) caused frameshifts.

Samples were stratified into 10 groups on the...
basis of the presence or absence of known recurring fusion events, cytogenetic-risk profile, or the presence or absence of TP53 mutations (which were strongly associated with an unfavorable cytogenetic risk) (Fig. 1A). We observed significant differences in the numbers of recurrent tier 1 mutations in some of these groups. Eleven samples had MLL fusions; this group had the fewest recurrent tier 1 mutations, with a mean of 2.09, as compared with a mean of 5.24 for all 200 samples (P=0.002 after correction for multiple comparisons). This finding suggests that MLL fusions require fewer cooperating mutations than other AML-initiating events. Similarly, 20 samples containing PML-RARA fusions had fewer recurrent tier 1 mutations (mean, 3.25; P=0.001). We observed a higher mean number of recurrent tier 1 mutations in 7 samples containing either RUNXI-RUNXIT1 fusions (mean value, 7.85; P=0.04) and in 13 samples with a combination of a high-risk cytogenetic profile and a TP53 mutation (mean, 7.00; P=0.049). Larger sample sets will be required to confirm these observations.

A total of 260 genes had somatic mutations in at least 2 of the 200 samples; in 154 of these genes, more than one mutation was nonsynonym-

<table>
<thead>
<tr>
<th>Table 1. Characteristics of the 200 Patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
</tr>
<tr>
<td>Age at study entry — yr</td>
</tr>
<tr>
<td>Race or ethnic group — no. (%)†</td>
</tr>
<tr>
<td>White</td>
</tr>
<tr>
<td>Black</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Male sex — no. (%)</td>
</tr>
<tr>
<td>Bone marrow blasts at diagnosis — %</td>
</tr>
<tr>
<td>Normal cytogenetic profile — no./total no. (%)</td>
</tr>
<tr>
<td>White-cell count at diagnosis — per mm³</td>
</tr>
<tr>
<td>Mean</td>
</tr>
<tr>
<td>Median</td>
</tr>
<tr>
<td>Cytogenetic risk group — no. (%)</td>
</tr>
<tr>
<td>Favorable</td>
</tr>
<tr>
<td>Intermediate</td>
</tr>
<tr>
<td>Unfavorable</td>
</tr>
<tr>
<td>Missing data</td>
</tr>
<tr>
<td>AML FAB subtype — no. (%)</td>
</tr>
<tr>
<td>AML with minimal maturation: M0</td>
</tr>
<tr>
<td>AML without maturation: M1</td>
</tr>
<tr>
<td>AML with maturation: M2</td>
</tr>
<tr>
<td>Acute promyelocytic leukemia: M3</td>
</tr>
<tr>
<td>Acute myelomonocytic leukemia: M4</td>
</tr>
<tr>
<td>Acute monoblastic or monocytic leukemia: M5</td>
</tr>
<tr>
<td>Acute erythroid leukemia: M6</td>
</tr>
<tr>
<td>Acute megakaryoblastic leukemia: M7</td>
</tr>
<tr>
<td>Other subtype</td>
</tr>
<tr>
<td>Immunophenotype — no./total no. (%)</td>
</tr>
<tr>
<td>CD13+</td>
</tr>
<tr>
<td>CD33+</td>
</tr>
<tr>
<td>CD34+</td>
</tr>
<tr>
<td>CD117+</td>
</tr>
</tbody>
</table>
An additional 1623 genes were found to have a validated tier 1 mutation in one sample. Using the significantly mutated gene (SMG) test in the Mutational Significance in Cancer (MuSiC) suite of tools, we identified 23 genes with a higher-than-expected mutation prevalence (false discovery rate, <0.05), including genes that are well established as being relevant to AML pathogenesis (e.g., DNMT3A, FLT3, NPM1, IDH1, IDH2, and CEBPA), along with genes that have only recently been implicated in AML pathogenesis, including U2AF1, EZH2, SMC1A, and SMC3 (Fig. 1B, and Table S7 in the Supplementary Appendix).

We also identified and verified all variants in noncoding regions in the 50 sample pairs that we analyzed using whole-genome sequencing. After the exclusion of 1 tumor sample, from Patient 817156, that had a high level of AML tumor cells (36%) in the skin sample (Table S1 in the Supplementary Appendix), the median number of non-coding mutations in tumor samples was 394, ranging from 68 to 1298. There was a strong correlation between the number of coding and noncoding mutations in each genome (Pearson’s correlation coefficient, 0.78), suggesting that most of the mutations were randomly distributed throughout each genome. Most mutations in AML genomes are probably background events that occurred in hematopoietic stem cells before the initiating event occurred; the clonal expansion of these cells captures their mutational history, as reportedly previously. This is also the reason why nearly all mutations in AML genomes are present in nearly all the cells in each sample. The results of an analysis of recurrently mutated regions in tiers 2 and 3 (nongenic regions) are presented in Table S8 in the Supplementary Appendix, as are data for mitochondrial variants (Table S9 in the Supplementary Appendix); the relevance of these events to pathogenesis is unclear.

Using deep digital sequencing, we verified all tier 2 and 3 variants that were discovered with the use of whole-genome sequencing. This provided a large number of sites for variant allele frequency (VAF)–based cluster analysis, which allowed us to

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation — no./total no. (%)</td>
<td></td>
</tr>
<tr>
<td>NPM1</td>
<td>54/200 (27)</td>
</tr>
<tr>
<td>FLT3</td>
<td>56/200 (28)</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>51/200 (26)</td>
</tr>
<tr>
<td>IDH1 or IDH2</td>
<td>39/200 (20)</td>
</tr>
<tr>
<td>NRAS or KRAS</td>
<td>23/200 (12)</td>
</tr>
<tr>
<td>RUNX1</td>
<td>19/200 (10)</td>
</tr>
<tr>
<td>TET2</td>
<td>17/200 (8)</td>
</tr>
<tr>
<td>TP53</td>
<td>16/200 (8)</td>
</tr>
<tr>
<td>CEBPA</td>
<td>13/200 (6)</td>
</tr>
<tr>
<td>WT1</td>
<td>12/200 (6)</td>
</tr>
<tr>
<td>PTPN11</td>
<td>9/200 (4)</td>
</tr>
<tr>
<td>KIT</td>
<td>8/200 (4)</td>
</tr>
<tr>
<td>Loss of 5 or del(5q)</td>
<td>16/195 (8)</td>
</tr>
<tr>
<td>Loss of 7 or del(7q)</td>
<td>20/195 (10)</td>
</tr>
<tr>
<td>11q23</td>
<td>7/195 (4)</td>
</tr>
<tr>
<td>t(15;17)</td>
<td>18/195 (9)</td>
</tr>
<tr>
<td>t(8;21)</td>
<td>7/195 (4)</td>
</tr>
<tr>
<td>inv(16)</td>
<td>12/195 (6)</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. AML denotes acute myeloid leukemia, and FAB French–American–British classification.
† Race or ethnic group was self-reported.
define the clonal composition of each tumor. More than half the tumors contained both a founding clone (the clone with the highest VAF values) and at least one subclone; we were able to identify as many as three independent subclones in one tumor sample (Fig. 1C, and Table S1 in the Supplementary Appendix). The coverage provided by whole-genome sequencing in this study (mean, 30.54×) limited the power to detect small subclones with VAFs of less than 10% (Fig. S3A in the Supplementary Appendix). Exome sequencing defined too few mutations to accurately define subclones. Each sample contained evidence of a single founding clone, and most had one or more subclones derived from the founding clone. The French–American–British (FAB) subtypes of the samples are designated. (See Table 1 for FAB subtypes of AML.)

Figure 1. Characterization of Mutations.
Panel A shows the numbers of verified, recurrent tier 1 mutations in each of 200 samples obtained from patients with AML, organized according to important cytogenetic and mutational findings. For each set of data, the middle horizontal line indicates the mean, and the shaded area indicates ±1 SD. P values are shown for the groups that had significant differences from the mean number of recurrent tier 1 mutations in all samples. NK denotes normal karyotype. Panel B shows significantly mutated genes, as identified by the MuSiC analysis suite, and the number of samples with each mutation. Panel C shows the number of discrete clusters of mutations with distinct variant allele frequencies (VAFs) for each of 50 samples that underwent whole-genome sequencing. Each discrete VAF cluster represents a founding clone or a subclone derived from it. Samples with one clone have only a founding clone, those with two clones have a founding clone and one subclone, those with three clones have a founding clone and two subclones, and so forth. Exome sequencing defined too few mutations to accurately define subclones. Each sample contained evidence of a single founding clone, and most had one or more subclones derived from the founding clone. The French–American–British (FAB) subtypes of the samples are designated. (See Table 1 for FAB subtypes of AML.)
targeted sequences (mean, 167.50×), slightly increasing our ability to detect mutations with VAFs of less than 10%. However, the difference between the number of tier 1 mutations detected with whole-genome sequencing (14.5 per sample) and the number detected with exome sequencing (12.7 per sample) was not significant (P = 0.17) (Table S6 in the Supplementary Appendix). The mutational spectrum of all validated SNVs for all 200 samples is shown in Figure S3B in the Supplementary Appendix; transitions were the most common mutation type, as reported previously.17,18

**Germline Variants**

We identified all the variants predicted to cause mRNA truncation that were found in both the skin and tumor samples (see the Results section, Table S11, and Fig. S6 in the Supplementary Appendix). However, very few of the genes with truncation variants were found to be expressed in most AML samples (including the samples carrying the variants themselves), suggesting that most of the inherited truncating variants were probably irrelevant for pathogenesis.

**Functional Categorization of Mutated Genes**

We used complementary approaches to identify combinations of mutations in the samples; for this analysis, we considered only nonsynonymous mutations (Fig. 2). Using the HotNet algorithm,27 we identified six subnetworks of a genome-scale protein–protein interaction network that had significant mutations (P < 0.001). These included portions of known pathways and protein complexes, including the cohesin complex17 (Fig. S7 in the Supplementary Appendix).

We grouped mutations into larger sets or pathways and examined patterns of mutual exclusivity and co-occurrence between these groups. Of 200 samples, 199 (>99%) contained at least one mutation in one of nine categories that were defined according to biologic function and that have a putative role in AML pathogenesis: transcription-factor fusions (18% of cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%), DNA-methylation–related genes (44%), activated signaling genes (59%), chromatin-modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and spliceosome-complex genes (14%) (Fig. 2, and Fig. S8 in the Supplementary Appendix). For all genes that had mutations in only a small number of samples, the pathophysiologic relevance of the events will require further validation.

FLT3 mutations were identified in 56 samples, and an additional 62 samples were found to have mutations in genes encoding other kinases, phosphatases, or RAS family proteins (Fig. S9 in the Supplementary Appendix). However, most of these genes contained mutations in only 1 to 3 samples (with the exception of KIT, KRAS, NRAS, and PTPN11). In total, 59% of samples had a mutation in a gene encoding a signaling protein.

To more fully assess patterns of mutual exclu-
sivity and co-occurrence between sets of genes, we applied Dendrix++ (see the Materials section in the Supplementary Appendix) to the mutation matrix. Dendrix++ identified three sets of genes with the strongest patterns of mutual exclusivity (groups A, B, and C) (Fig. 2). The most statistically significant set included the transcription factors also showed considerable epigenetic modifiers, and genes encoding myeloid family proteins (Fig. S9 in the Supplementary Appendix). The third set included mutations in ASXL1 and in genes encoding components of the cohesin complex, other myeloid transcription factors, and other epigenetic modifiers (Fig. S10 in the Supplementary Appendix). Mutations within the spliceosome gene set, genes encoding other epigenetic modifiers, and genes encoding myeloid transcription factors also showed considerable mutual exclusivity within each set (Fig. S11 in the Supplementary Appendix).

Among the pairwise relationships between mutations in the AML samples, the most prominent was the significant co-occurrence between mutations in FLT3, DNMT3A, and NPM1 (Fig. S8 in the Supplementary Appendix). In particular, many samples had mutations both in NPM1 and DNMT3A or in NPM1 and FLT3. The likelihood that these mutations occurred together by chance is extremely small (P<6.3×10⁻⁷ for NPM1 and DNMT3A and P<1.9×10⁻⁶ for NPM1 and FLT3). This observation, combined with the strong association between samples having concurrent mutations in NPM1, FLT3, and DNMT3A and distinct clusters in mRNA, miRNA, and DNA methylation, suggests that samples with mutations in all three genes represent a novel subtype of AML. Furthermore, we observed relationships of strong mutual exclusivity. For example, PML-RARA, MYH11-CBFB, and MLL-containing fusion genes were mutually exclusive of mutations in NPM1 and DNMT3A (P<0.007, P<0.04, and P<0.04, respectively), and RUNX1 and TP53 mutations were mutually exclusive of FLT3 and NPM1 mutations. Table S12 in the Supplementary Appendix contains a full list of genes or gene sets with significant co-occurrences or exclusivity among the samples.

**GENE FUSIONS**

De novo assembly of RNA-sequencing data for 179 AML samples identified 118 gene fusions in 80 samples (mean, 1.5 per sample), of which 71 were distinct events (Fig. 3A)⁹; 99 samples had no detected fusions (Table S13 in the Supplementary Appendix). The range of fusions per sample was 0 to 8. The 74 in-frame fusions included many previously described, recurrent events, including PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1, BCR-ABL1, PICALM-MLLT10(AF10, NUP98-NSD1, and multiple fusions involving MLL (Fig. 3B). We identified 15 new fusion events that maintained an open reading frame. Although none of them were recurrent in this cohort, several of the genes in the fusions were mutated or translocated in other samples of AML that we analyzed (i.e., MLLT10(AF10, NF1, GRID1, PPP2R1B, XIAP, ATP1B4, WSB1, KIAA0999, TBX15, and LRRC37B). An additional 42 gene fusions were out-of-frame (Fig. 3C), creating a truncated upstream gene or potential haploinsufficiency for both partner genes, with many that were mutated or translocated in other AML samples (including RUNX1, DNMT3B, MLLT10(AF10, NSD1, EDIL3, SCARBL1, XIAP1, PPP2R1B, FOXP1, KSR2, MLL3, and CUL1). One out-of-frame fusion (GAS6-FAM70B) was detected in three AML samples, and one of its fusion partners (FAM70B) was mutated in another sample. Most of the newly described fusion events in these samples were not detected by means of routine cytogenetic studies (Table S1 in the Supplementary Appendix).
Figure 3. AML Gene Fusions.

Panel A is a plot created with the use of Circos software showing in-frame (green) and out-of-frame (orange) gene fusions detected in the AML cohort in the Cancer Genome Atlas (TCGA) with the use of Trans-ABySS software. Ribbon widths are proportional to the frequency of a fusion event. Chromosomes are individually colored and are arranged clockwise from chromosome 1 to X, starting with chromosome 1 at 12 o’clock. No rearrangements involved the Y chromosome. The frequencies of in-frame and out-of-frame gene fusions are shown in Panels B and C, respectively. For gene names shown in red, one of the partner genes in that fusion was found to be mutated in at least one other AML sample from this data set. On the basis of chromosomal aberrations and genomic variants annotated in the Mitelman database from the Cancer Genome Anatomy Project (CGAP) (http://cgap.nci.nih.gov/Chromosomes/Mitelman), all previously identified gene fusions are shown in blue, a single known polymorphic fusion is shown in green, and all novel events are shown in red.
Gene-Expression Analysis

Unsupervised non-negative matrix factorization (NMF) consensus clustering (i.e., clustering data with inputs consisting only of gene or miRNA abundance information) suggested an optimum of seven RNA-sequencing groups and five miRNA-sequencing groups (Fig. S12 in the Supplementary Appendix). Associations between these groups...
and overall survival are shown in Fig. S13 in the Supplementary Appendix; the groups enriched for samples containing PML-RARA had better outcomes than other groups, as expected. The RNA-seq groups were highly concordant with a microarray data set for the same 178 samples (Fig. S14 in the Supplementary Appendix). We used one-sided Fisher’s exact tests (corrected for multiple testing) to identify significant associations (P<0.05) between specific RNA-seq and miRNA-seq groups and covariates (Fig. 4). RNA-seq group 4 was associated with subtype M1 (AML with minimal maturation) in the French–American–British (FAB) classification of acute leukemias, group 3 with FAB subtype M3 (acute promyelocytic leukemia), group 5 with FAB subtype M4 (acute myelomonocytic leukemia), and group 7 with FAB subtype M5 (acute monoblastic or monocytic leukemia) (Fig. 4A). Concordance between gene-expression groups and FAB subtypes was similar to that previously reported for microarray data and showed that some expression signatures were strongly correlated with the stage of myeloid differentiation of the AML sample.

For the miRNA-seq data, group 5 was associated with FAB subtype M3, and groups 2, 3, and 5 were associated with unfavorable, intermediate, and favorable cytogenetic risk categories, respectively. Group 3 was strongly associated with mutations in NPM1, DNMT3A, FLT3, and genes encoding the cohesin complex; miR-10a was expressed at high levels in this group, an observation that is consistent with reports correlating high miR-10a expression and NPM1 mutations (Fig. 4B). Levels of miR-424 were relatively low in this group, making miR-424 the second-most discriminatory miRNA — an observation that is consistent with the findings in a previous study.

The data also confirmed that miR-196b, miR-130a, and let-7b were discriminatory in this group. Additional comparisons with published sets of expression data are provided in the Materials section in the Supplementary Appendix.

**DNA-Methylation Analysis**

Unsupervised analysis of changes in DNA methylation revealed significant differences among subsets of samples, particularly in CpG-sparse regions of the genome (Fig. 5). Samples with IDH1 and IDH2 mutations showed extensive gains of methylation relative to CD34+CD38− cells obtained from healthy donors (Table S14 in the Supplementary Appendix), whereas some samples with MLL fusions or co-occurring NPM1, DNMT3A, and FLT3 mutations were associated with extensive loss of DNA methylation, as compared with normal CD34+CD38− cells. Specific patterns of methylation gain and loss distinguished samples with CEBPA mutations, as well as samples with PML-RARA, RUNX1-RUNXIT1, or MYH11-CBF8 fusions. Significant changes in DNA methylation were identified across AML samples at 160,519 CpG loci (42% of sites tested), with 67% resulting in a gain of methylation and 33% resulting in a loss (see the Methods section and Table S15 in the Supplementary Appendix). Samples with triple mutations in NPM1, DNMT3A, and FLT3 showed methylation losses at 328 of 382 differentially methylated regions larger than 1 kb (86%), as compared with CD34+CD38− cells from healthy donors. Although both intergenic and genic regions were affected, approximately 71% of these changes were in coding regions (Table S16 in the Supplementary Appendix).

We also assessed the relationships between gene expression and DNA methylation in pairs of data types by identifying groups in one data type that were enriched in samples from a group in the other data type (Fig. S15A through S15E in the Supplementary Appendix). Clusters containing samples of acute promyelocytic leukemia were strongly concordant for mRNA, miRNA, and CpG-sparse DNA methylation (Fig. 5, and Fig.
S15 in the Supplementary Appendix). In mRNA groups 1, 2, 5, and 6, there was a preferential association with one miRNA-sequencing group each, suggesting that regulatory relationships must exist between these groups (Fig. S15A in the Supplementary Appendix). Associations in CpG-sparse DNA methylation groups were more significant for miRNA groups than for mRNA groups, suggesting the existence of previously unrecognized epigenetic regulatory pathways (Fig. S15B through S15E in the Supplementary Appendix). Genes defining the RNA- and miRNA-sequencing groups are shown in Figure S16 in the Supplementary Appendix; a very striking set of small RNA genes within an imprinted locus on chromosome 14 were found to be consistently dysregulated in acute promyelocytic leukemia (Fig. S17 in the Supplementary Appendix).37

**DISCUSSION**

Of the adult cancer types that have been extensively sequenced to date, AML has had the fewest mutations discovered (Fig. S18 in the Supplementary Appendix). The average number of coding mutations (SNVs and indels) per patient in this study was 13, of which only 5 were recurrently mutated in each genome. There was little evidence of genomic instability in most AML genomes. However, a small number of patients had an unfavorable-risk (complex) cytogenetic profile that was strongly associated with mutations in TP53, which confirmed a recently reported relationship.38 Adult AML genomes contain a median of only one somatic copy-number variant and an average of less than one gene-fusion event (generally caused by translocations).1,2

The organization of mutated genes into nine functionally related categories revealed many potentially important biologic relationships. The transcription-factor fusions were the first recognized somatic mutations in AML genomes,1,2 and all such fusions have been shown to be relevant for disease initiation in mice.39-42 Our data show that some mutations that are common in AML (e.g., in DNMT3A, NPM1, CEPBA, IDH1/2, and RUNX1) are mutually exclusive of the transcription-factor fusions, suggesting that these mutations may have functions in the initiation of AML that are similar to the functions of fusion genes. We also identified a pattern of mutual exclusivity for mutations in genes within certain biologic classes, including those encoding the cohesins, proteins of the spliceosome, signaling proteins, and histone-modifying proteins, suggesting that one mutation in these pathways is generally adequate for AML pathogenesis. Although a common model of AML pathogenesis has suggested that an activating mutation in a gene encoding a signaling protein might be a requirement for pathogenesis,43 only 59% of the patients in our study had a mutation in a gene annotated to suggest a role in signaling.

We integrated the expression data for both mRNA and miRNA with all the clinical and mutational data for all genomes. That analysis revealed that the differentiation state of the AML sample was highly correlated with the expression signature, as reported previously.44 Patients who had PML-RARA fusions had very distinct mRNA and miRNA signatures that were strongly correlated with each other and with a specific DNA methylation signature.45 All the transcription-factor fusions were correlated with specific patterns of mRNA expression, whereas PML-RARA and RUNXI-RUNXIT1 (and some MLL fusions) were also associated with miRNA expression signatures. In addition, occurrence of NPM1, DNMT3A, and FLT3 mutations together was strongly associated with specific expression signatures for both mRNA and miRNA. These data suggest that this combination of mutations in patients with intermediate-risk AML may identify a subtype of AML with unique epigenetic features. Our analysis of methylation patterns corroborates previous reports of methylation signatures in CpG islands for transcription-factor fusions and IDH1/2 mutations46,47 but surprisingly revealed that the strongest methylation signatures occur in CpG-sparse regions of the genome. Although the significance of this finding is not yet clear, the widespread and variable losses of methylation in these regions are consistent with observations from analyses of epithelial tumors48 and support the idea that methylation patterns in gene bodies and intergenic regions are important for the regulation of gene expression.49

This data set will be available to provide a framework for future studies that pertain to the molecular classification of patients with AML. The identification of many potentially important relationships among recurrently mutated AML genes and pathways provides a comprehensive foundation for an understanding of the genetic rules of pathogenesis.
The views expressed in this article are those of the authors and do not reflect the official policy of the National Institutes of Health.

Supported by grants from the National Institutes of Health (U24CA143845, U24CA143858, U24CA144025, U24CA143882, U24CA143886, U24CA143867, U24CA143848, U24CA143840, U24CA143835, U24CA143799, U24CA143883, U24CA143843, U54HG003067, U54HG003079, U54HG003273, and PO1CA101977).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank our patients for participating in this study; J. Peek, H. Black, G. Carnoske, and N. Reidelberger for providing administrative support; and L. Lund for performing administrative coordination of TCGA activities.

APPENDIX

The authors (members of the Cancer Genome Atlas Research Network) and their affiliations are as follows: Timothy J. Ley, M.D., the Genome Institute at Washington University and Siteman Cancer Center, St. Louis; Christopher Miller, Ph.D., and Li Ding, Ph.D., the Genome Institute at Washington University; St. Louis; Benjamin J. Raphael, Ph.D., Brown University and Center for Computational Molecular Biology, Providence, R.I.; Andrew J. Mungall, Ph.D., and A. Gordon Robertson, Ph.D., British Columbia Cancer Agency’s Genome Sciences Centre, Vancouver, Canada; Katherine Hoadley, Ph.D., University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill; Timothy J. Triche, Jr., M.S., and Peter W. Laird, Ph.D., University of Southern California, Epigenome Center, Los Angeles; Jack D. Baty, B.A., Washington University, St. Louis; Lucinda L. Fulton, M.S., and Robert Fulton, M.S., the Genome Institute at Washington University, St. Louis; Sharon E. Heath, Washington University, St. Louis; Joelle Kalicki-Veizer, B.S., and Cyriac Kandoth, Ph.D., the Genome Institute at Washington University, St. Louis; Jeffery M. Kleo, M.D., Ph.D., Washington University, St. Louis; Daniel C. Koboldt, M.S., and Krishna-Latha Kanchi, M.S., the Genome Institute at Washington University, St. Louis; Shashikant Kulkarni, M.S., Ph.D., F.A.C.M.G., and Tamara L. Lamprecht, B.S., Washington University, St. Louis; David E. Larson, Ph.D., Ling Lin, M.S., Charles Lu, Ph.D., Michael D. McLe llan, B.S., and Joshua F. McMichael, B.S., the Genome Institute at Washington University, St. Louis; Jacqueline Payton, M.D., Ph.D., Washington University, St. Louis; Heather Schmidt, B.S., the Genome Institute at Washington University, St. Louis; David H. Spencer, M.D., Ph.D., Washington University, St. Louis; Michael H. Tomasson, M.D., Washington University and Siteman Cancer Center, St. Louis; John W. Wallis, Ph.D., the Genome Institute at Washington University, St. Louis; Lukas D. Wartman, M.D., Mark A. Watson, M.D., Ph.D., and John Welch, M.D., Ph.D., Washington University, St. Louis; Michael C. Wendt, Ph.D., the Genome Institute at Washington University, St. Louis; Ad rie nne B. Wood, M.S., Miruna Balasundaram, B.A.Sc., Inan c Birol, Ph.D., Yaron Butterfield, B.Sc., Readman Chiu, M.Sc., Andy Chu, B.Sc., Eric Chua, B.Sc., Hye-Jung Chun, M.Sc., Richard Corbett, M.Sc., Noreen Dhalla, B.Sc., Ranabir Guin, B.A.Sc., An He, M.Sc., Carrie Hirst, B.Sc., Martin Hirst, Ph.D., Robert A. Holt, Ph.D., Steven Jones, Ph.D., Aly Karsan, M.D., Darlene Lee, Hai y an L. Li, M.Sc., Marco A. Mar ra, Ph.D., Michael Mayo, B.Sc., Richard A. Moore, Ph.D., Karen Mungall, B.Sc., Jeremy Parker, Ph.D., Erin Pleasance, Ph.D., Patrick Plettn er, B.Sc., Jacque lie Schein, M.Sc., Dominik Stoll, Ph.D., Lu cinda S tirewalt, M.Sc., Angela Tam, B.Sc., Nina Thiessen, M.Sc., Richard Var hol, M.Sc., Natasja Wise, B.Sc., and Yongjun Zhao, M.Sc., D.V.M., British Columbia Cancer Agency’s Genome Institute, Vancouver, Canada; Stacey Gabel, B.Sc., Ph.D., Car rie Sougnez, B.S., and Li hua Zou, Ph.D., Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; Mark D.M. Leiser son, B.A., Fabio Vandi, B.Sc., and Hsin-Tu Wu, M.Sc., Brown University and Center for Computational Molecular Biology, Providence, RI; Frederick Applebaum, M.D., Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Seattle Cancer Care Alliance, Seattle; Stephen B. Baylin, M.D., Johns Hopkins University, Baltimore; Rehan Albani, Ph.D., Bradley M. Broom, Ph.D., Ken Chen, Ph.D., Thomas C. Motter, B.A., Khanh Nguyen, M.D., John N. Weinstein, M.D., Ph.D., and Nianziang Zhang, Ph.D., University of Texas M.D. Anderson Cancer Center, Houston; Martin L. Ferguson, Ph.D., MLF Consulting and Biotechnology Consultant, Boston; Christopher Adams, B.S., Aaron Black, B.A., Jay Bowen, M.S., Julie Gastier-Foster, Ph.D., Thomas Grossman, M.D., Ph.D., Taza Lichtenberg, B.A., and Lisa Wise, the Research Institute at Nationwide Children’s Hospital, Columbus, OH; Tanja Davi densen, Ph.D., John A. Demech, M.S., Kenna R. Mills Shaw, Ph.D., and Margi Sheth, B.S., National Cancer Institute, Bethesda, MD; Heidi J. Sofia, Ph.D., M.P.H., National Human Genome Research Institute, Bethesda, MD; Liming Yang, Ph.D., National Cancer Institute, Bethesda, MD; James R. Downing, M.D., St. Jude Children’s Research Hospital, Memphis; Greg Eley, Ph.D., Sciementis LLC, Statham, GA; Shelley Alonso, Brenda Ayala, B.Sc., Julien Baubou, M.S., Mark Backus, Ph.D., Sean P. Barlett, B.S., Dominique L. Berton, M.S.C.S., Anna L. Chua, B.Sc., Stanley Girshik, M.S., Mark A. Jensen, Ph.D., Ari Kain, Ph.D., Prachi Kothiyal, Ph.D., Matthew C. Nicholls, M.S., Todd D. Pihl, Ph.D., David A. Pot, Ph.D., Rohini Raman, B.E., Rashmi N. Sanhbhati, B.S., Eric E. Snyder, Ph.D., Deepak Srini vasan, M.S., Jessica Walton, M.S., Yunhu Wan, Ph.D., and Zhiqing Wang, Ph.D., SRA International, Fairfax, VA; Jean-Pierre J. Issa, M.D., Temple University, Philadelphia; Michelle Le Beau, Ph.D., University of Chicago, Chicago; Martin Carroll, M.D., University of Pennsylvania, Philadelphia; Hagop Kantarjian, M.D., and Steven Kornblau, M.D., University of Texas M.D. Anderson Cancer Center, Houston; Moi z S. Bootwalla, B.S., M.Sc., M.S., Phillip H. Lai, B.Sc., Hui Shen, B.Sc., David J. Van Den Berg, Ph.D., and Daniel J. Weisbener, Ph.D., University of Southern California, Epigenome Center, Los Angeles; Daniel C. Link, M.D., and Matthew J. Walter, M.D., Washington University and Siteman Cancer Center, St. Louis; Bradley A. Ozenberger, Ph.D., National Human Genome Research Institute, Bethesda, MD; Elaine R. Mardis, Ph.D., the Genome Institute at Washington University, St. Louis; Peter Westervelt, M.D., Ph.D., Timothy A. Graubert, M.D., and John F. DiPersio, Ph.D., Washington University and Siteman Cancer Center, St. Louis; and Richard K. Wilson, Ph.D., the Genome Institute at Washington University, St. Louis.

The references are:


REFERENCES

The New England Journal of Medicine

Copyright © 2013 Massachusetts Medical Society. All rights reserved.


10. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leu-


14. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumu-

15. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute my-
eloid leukemia in adults: recommenda-


18. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leu-
kemia revealed by whole-genome se-


20. Dees ND, Zhang Q, Kandoth C, et al. MuSiC: identifying mutational signifi-

21. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic line-


23. Xu J, Li D, Shi Q, Hou H, Sun N, Shen B. Differential microRNA expression in childhood B-cell precursor acute lympho-

24. Bellon M, Lepelletier Y, Hermine O, Nicot C. Deregression of microRNA in-

25. Lv M, Zhang X, Jia H, et al. An onco-
genic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia 2012;26:769-77.

26. Wang XS, Gong JN, Yu J, et al. Mi-

27. Vandin F, Upfal E, Raphael BJ. Algo-
rithms for detecting significantly mutat-


30. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular sub-

31. Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically useful gene-expres-

32. Bryant A, Palma CA, Jayaswal V, Yang YY, Lutherborrow M, Ma DD. miR-10a is aberrantly overexpressed in nucleophos-

33. Ovcharenko D, Stolzel F, Poitz D, et al. miR-10a overexpression is associated with NPM1 mutations and MDM4 down-
regulation in intermediate-risk acute my-

34. Corral J, Lavenir I, Impye H, et al. An MI-AP9 fusion gene made by homolo-
gous recombination causes acute leuke-


36. Payton JE, Grieselhuber NR, Chang LW, et al. High-throughput digital quanti-

37. De Croe I, Raker VA, Corsaro M, et al. Methylationtransferase recruitment and DNA hypermethylation of target promot-

38. Figueroa ME, Abdel-Wahab O, La C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hema-


40. Hansen KD, Ting W, Bravo HC, et al. Increased methylation variation in epi-


---

Copyright © 2013 Massachusetts Medical Society.